Lonza Group (OTCMKTS:LZAGY) Given New CHF 670 Price Target at Royal Bank of Canada

Lonza Group (OTCMKTS:LZAGY – Get Rating) had its target price upped by Royal Bank of Canada from CHF 650 to CHF 670 in a report released on Monday morning, The Fly reports.

Several other equities research analysts have also issued reports on the stock. Credit Suisse Group decreased their price target on shares of Lonza Group from CHF 750 to CHF 700 and set an outperform rating for the company in a research note on Thursday, July 7th. JPMorgan Chase & Co. decreased their price target on shares of Lonza Group from CHF 900 to CHF 770 in a research note on Monday, July 25th. Deutsche Bank Aktiengesellschaft decreased their price target on shares of Lonza Group from CHF 835 to CHF 702 and set a buy rating for the company in a research note on Wednesday, July 6th. Citigroup raised shares of Lonza Group from a neutral rating to a buy rating in a report on Tuesday, July 5th. Finally, Morgan Stanley cut their price objective on shares of Lonza Group from CHF 800 to CHF 785 and set an equal weight rating for the company in a report on Monday, April 4th. One equities research analyst has rated the stock with a hold rating and seven have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, the company currently has an average rating of Moderate Buy and a consensus target price of $725.40.

Lonza Group Trading Up 0.3 %

OTCMKTS:LZAGY opened at $60.56 on Monday. The firm has a 50-day moving average price of $56.04 and a two-hundred day moving average price of $62.36. Lonza Group has a 52 week low of $49.70 and a 52 week high of $86.31.

Lonza Group Dividend Announcement

The company also recently declared a dividend, which was paid on Thursday, May 26th. Shareholders of record on Tuesday, May 10th were issued a $0.0895 dividend. This represents a yield of 0.39%. The ex-dividend date was Monday, May 9th.

About Lonza Group

(Get Rating)

Lonza Group Ltd supplies products and services to the pharmaceutical, biotech, and nutrition markets in Switzerland and internationally. It operates through Biologics, Small Molecules, Cell and Gene, and Capsules and Health Ingredients divisions. The Biologics division engages in the contract development and manufacturing services for biopharmaceuticals.

Read More

• Get a free copy of the StockNews.com research report on Lonza Group (LZAGY)
• MarketBeat Podcast: Find Investing Opportunities For The Rest of 2022
• Deep Value High Yield Newell Brands Is Ready To Bottom 
• The Colgate-Palmolive Growth Outlook Brightens 
• These Stocks Outperformed Last Time There Was A Recession
• Does Rivian’s Stock Still Have A Future?

Want More Great Investing Ideas?